Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth

Naomi A. van Westen-Lagerweij1,2✉, Eline Meijer3, Elisabeth G. Meeuwsen3, Niels H. Chavannes4, Marc C. Willemsen1,2 and Esther A. Croes1

A number of recent studies have found low percentages of smokers among COVID-19 patients, causing scientists to conclude that smokers may be protected against SARS-CoV-2 infection. National and international media were interested in this story and we soon began receiving questions about this topic in general practice. In this article, we shed light on the process that resulted in the misinterpretation of observational research by scientists and the media. We also point out the methodological flaws of various studies on which hasty conclusions were based. Finally, we address the role of primary healthcare providers in mitigating the consequences of erroneous claims about a protective effect of smoking.

npj Primary Care Respiratory Medicine (2021) 31:10; https://doi.org/10.1038/s41533-021-00223-1

Recently, a number of observational studies found an inverse relationship between smoking and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 (COVID-19)), leading to a (social) media hype and confusion among scientists and to some extent the medical community. The finding that smoking is not associated with SARS-CoV-2 infection contradicts earlier studies which found that smokers are more vulnerable to infections in general and to respiratory infections in particular. Smoking is known to increase the risk of infection of both bacterial and viral diseases, such as the common cold, influenza and tuberculosis, and smoking is a putative risk factor for Middle East respiratory syndrome coronavirus infection. Could it be possible that SARS-CoV-2 is the big exception to the rule? To date, there is no strong evidence (i.e., evidence based on causal research) that smokers are protected against SARS-CoV-2 infection. Moreover, there is growing evidence that smokers have worse outcomes after contracting the virus than non-smokers.

It seems the tobacco industry benefited from the (social) media hype, since exposure to claims about a protective effect of smoking was associated with an increase in tobacco consumption among Chinese citizens during the pandemic. Also in other countries, an increase in tobacco consumption among smokers has been reported, possibly influenced by this hype. In France, researchers first suggested that nicotine may play a role in protecting smokers, triggering a run on nicotine products among the general public. Interestingly, the lead author of this research has been funded by the tobacco industry in the past, and also other researchers who have made similar claims can be linked with the tobacco industry, indicating a possible conflict of interest. According to the Global Center for Good Governance in Tobacco Control, the tobacco industry was actively involved in downplaying the role of smoking in COVID-19 by spreading claims that smoking or vaping protects against COVID-19.

So, what research was this claim based on in the first place? In the early months of the COVID-19 pandemic, most studies describing the relationship between smoking and COVID-19 were based on Chinese patient groups. These studies, in which smoking status was not a primary exposure of interest, were subsequently brought together in several systematic reviews and meta-analyses. Soon after, hospital data from other countries became available. Overall, the findings suggested that smokers were underrepresented among COVID-19 patients based on the prevalence of smoking in the general population. The studies, however, made comparisons without adjusting for a number of factors that are associated with smoking status, such as age, gender, socio-economic status, ethnicity and occupation. The studies also contained other major methodological flaws, including incompleteness of data (the majority of the studies had >20% missing data on smoking status), selection bias and misclassification bias. Here we use two examples (one Chinese and one French study) to illustrate the most common problems with these studies.

1. Guan et al. is one of the largest Chinese studies on smoking and COVID-19, with data on 1590 patients from 575 hospitals across China. Interestingly, the scientists received

1The Netherlands Expertise Centre for Tobacco Control, Trimbos Institute, Utrecht, The Netherlands. 2Department of Health Promotion, Maastricht University, Maastricht, The Netherlands. 3Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. ✉email: NLagerweij@trimbos.nl

Published in partnership with Primary Care Respiratory Society UK
mostly one patient file per hospital. It is unclear on what grounds these patients were selected for inclusion in the study. Furthermore, 93% of all patients were categorised as: ‘smoking status: never/unknown’. According to a peer reviewer of a different study, ‘unknown’ can be explained by the fact that many patients were too ill to answer the questions about smoking. When we look more closely at specific patient groups in the data, we see that, of the 24 included chronic obstructive pulmonary disorder (COPD) patients, only 3 had ever smoked (12.5%); the other 21 patients are found in the category ‘smoking status never/unknown’. This is quite remarkable, considering that smoking is the most important risk factor for COPD, causing up to 80% of all cases. Guan et al. also found an unusually low number of smokers among patients with a cardiovascular or cerebrovascular disease.

2. A university hospital in Paris appears to have collected their data more systematically: they asked 482 COVID-19 patients whether they smoked or had done so in the past, resulting in only 9 missing answers. They reported only 5% of current daily smokers in their patient group. But what was left out of the (media) attention was that 32% of patients reported being former smokers, defined as ‘anyone having smoked in the past, occasionally or daily, and had abstained from smoking prior to COVID-19 onset’. This definition allows individuals to have been a smoker the day before development of COVID-19 symptoms. There were more serious limitations of this study: a relatively small patient unit. This may, for example, apply to patients with serious and COVID-19 patients have severe comorbidities that may and COVID-19 among the general public are expelled, especially considering the growing evidence that smokers have worse long-term smoking. Second, many smokers have already died of smoking-related illnesses (far) before they reach the age of the average COVID-19 hospital inpatient (around 68 years). And the final and most important reason is that hospital data are collected cross-sectionally (i.e. determining risk factor and disease at the same time). In epidemiology, cross-sectional studies are the weakest form of observational studies. The highest achievable outcome in cross-sectional research is to find a correlation, not causation. Only cohort studies of sufficient size, in which a group of patients is followed over a longer period of time, would be able to determine whether smokers are actually protected against SARS-CoV-2 infection or not.

In the meantime, it is imperative that any myths about smoking and COVID-19 among the general public are expelled, especially considering the growing evidence that smokers have worse outcomes once infected. There is no easy solution to the spread of health misinformation through social media, but primary healthcare providers (HCPs) can play an important role in mitigating its harmful effects. What are some practical steps primary HCPs can take? First, in line with national guidelines, primary HCPs can choose to ask patients about their smoking status during consultations, inform smokers about the dangers of smoking, advise smokers to quit smoking and offer cessation support to all smokers. As face-to-face cessation support may now be limited, primary HCPs can point out the availability of support at a distance, such as telephone quitlines or eHealth interventions. Second, primary HCPs can inform patients about the harmful relationship between smoking, COVID-19 and other serious illnesses, for example, by addressing the issue on their website or on posters/television screens in the waiting room. We encourage HCPs to use the information provided by recognised international organisations, such as the World Health Organisation. Third, since exposure to health misinformation on social media is more common among youth and young adults, primary HCPs may choose to actively bring up the subject of smoking and COVID-19 in consultations with youth and young adults and advise non-smokers to never start smoking.

A HCP’s advice for smoking cessation has always been very important, but in these COVID-19 times it is more urgent than ever before.

Received: 15 October 2020; Accepted: 3 February 2021; Published online: 26 February 2021

REFERENCES

1. Arcavi, L. & Benowitz, N. L. Cigarette smoking and infection. Arch. Intern. Med. 164, 2206–2216 (2004).
2. Alraddadi, B. M. et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg. Infect. Dis. 22, 49–55 (2016).
3. Simons, D., Shahab, L., Brown, J. & Perski, O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction (2020).
4. Kodvani, J., Homolak, J., Virag, D. & Trikula V. Publishing of COVID-19 preprints in peer-reviewed journals, preprinting trends, public discussion and quality issues. Preprint at bioRxiv. https://www.biorxiv.org/content/10.1101/2020.11.23.394573v3 (2020).
5. Lachapelle, F. COVID-19 preprints and their publishing rate: an improved method. Preprint at MedRxiv https://www.medrxiv.org/content/10.1101/2020.09.20.20188771v4 (2020).
6. Luk, T. T. et al. Exposure to health misinformation about COVID-19 and increased tobacco and alcohol use: a population-based survey in Hong Kong. Tob. Control https://doi.org/10.1136/tobaccocontrol-2020-059460 (2020).
7. Bommelé, J. et al. The double-edged relationship between COVID-19 stress and smoking: Implications for smoking cessation. Tob. Induc. Dis. 18, 63 (2020).
8. Klemperer, E. M., West, J. C., Peasley-Miklus, C. & Villanti, A. C. Change in tobacco and electronic cigarette use and motivation to quit in response to COVID-19. Nicotine Tob. Res. 22, 1662–1663 (2020).
9. Changeux, J. P., Amoura, Z., Rey, F. A. & Miyara, M. A nicotinic hypothesis for COVID-19 with preventive and therapeutic implications. C. R. Biol. 343, 33–39 (2020).
10. COVID-19 and Tobacco Industry Interference (2020). Global center for good governance in tobacco control. https://ggtc.world/2020/03/24/covid-19-and-tobacco-industry-interference-2020/ (2020).
11. Guan, W. J. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 55, 490054 (2020).
12. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
13. Liu, J. et al. Epidemiological, clinical characteristics and outcome of medical staff infected with COVID-19 in Wuhan, China: a retrospective case series analysis. Preprint at MedRxiv https://www.medrxiv.org/content/10.1101/2020.03.09.20033118v1 (2020).
14. Mo, P. et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa270 (2020).
15. Wan, S. et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J. Med. Virol. 92, 797–806 (2020).
16. Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475–481 (2020).
17. Zhang, J. J. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75, 1730–1741 (2020).
AUTHOR CONTRIBUTIONS

Based on the earlier work of E.A.C., N.A.v.W.-L. wrote the first and subsequent versions of the manuscript. E.M., E.G.M., N.H.C., M.C.W. and E.A.C. provided critical review of the manuscript. All authors approved the final version for submission.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to N.A.v.W.-L.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021